FindTrial
Sign In

PBO

DRUG5 trials

Sponsors

Pfizer, Orexigen Therapeutics, Inc, Eisai Inc., argenx, Eisai Co., Ltd.

Conditions

Active Idiopathic Inflammatory MyopathyAntisynthetase SyndromeDermatomyositisHealthy SubjectsHypercholesterolemiaImmune-Mediated Necrotizing MyopathyMyositisObesity

Phase 1

Crossover Study to Evaluate the Effect of Lemborexant Versus Placebo and Zolpidem on Postural Stability, Auditory Awakening Threshold, and Cognitive Performance in Healthy Subjects 55 Years and Older
CompletedNCT03008447
Eisai Inc.Healthy Subjects
Start: 2016-11-21End: 2018-01-03Updated: 2019-08-01

Phase 2

Monthly And Twice Monthly Subcutaneous Dosing Of PF-04950615 (RN316) In Hypercholesterolemic Subjects On A Statin
CompletedNCT01592240
PfizerHypercholesterolemia
Start: 2012-07-31End: 2013-05-31Updated: 2017-12-05
A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Active Idiopathic Inflammatory Myopathy.
Active, not recruitingNCT05523167
argenxActive Idiopathic Inflammatory Myopathy, Antisynthetase Syndrome, Dermatomyositis +3
Start: 2022-10-12End: 2027-02-01Updated: 2025-07-23
A Study to Assess the Pharmacodynamics of Lemborexant in Korean Participants With Insomnia Disorder
CompletedNCT05594589
Eisai Co., Ltd.Sleep Initiation and Maintenance Disorders
Start: 2022-11-30End: 2024-05-24Updated: 2025-07-03

Phase 3

Cardiovascular Outcomes Study of Naltrexone SR/Bupropion SR in Overweight and Obese Subjects With Cardiovascular Risk Factors (The Light Study)
TerminatedNCT01601704
Orexigen Therapeutics, IncObesity, Overweight
Start: 2012-06-30End: 2015-08-31Updated: 2017-02-27

Related Papers

0550 Lemborexant’s Effects on Rapid Eye Movement (REM) Sleep Architecture in Asian and Non-Asian Adults with Insomnia: Comparative Analysis from 3 Studies
SLEEP2025-05-01
Efficacy and safety of insomnia treatment with lemborexant in older adults: analyses from three clinical trials
Drugs & Aging2024-08-0910 citations
Effect of Naltrexone-Bupropion on Major Adverse Cardiovascular Events in Overweight and Obese Patients With Cardiovascular Risk Factors: A Randomized Clinical Trial
UNC Libraries2020-04-1823 citations
Safety of lemborexant versus placebo and zolpidem: effects on auditory awakening threshold, postural stability, and cognitive performance in healthy older participants in the middle of the night and upon morning awakening.
2020-02-0649 citations
Effect of Naltrexone-Bupropion on Major Adverse Cardiovascular Events in Overweight and Obese Patients With Cardiovascular Risk Factors
JAMA2016-03-08264 citations
Results of bococizumab, a monoclonal antibody against proprotein convertase subtilisin/kexin type 9, from a randomized, placebo-controlled, dose-ranging study in statin-treated subjects with hypercholesterolemia.
2015-02-12135 citations